Committed to Helping People With PAH
TYVASO is produced by United Therapeutics Corporation, a biotechnology company founded by Martine and Bina Rothblatt in 1996 after their daughter was diagnosed with pulmonary arterial hypertension (PAH). United Therapeutics was born from a very personal and passionate desire to develop medicines that could help their daughter and others suffering from this rare disease.
We are committed to helping people affected by PAH.
– Martine Rothblatt
Chairperson and CEO,United Therapeutics Corporation
A Personal Note From Our Founder
When our daughter was diagnosed with PAH, almost no treatment options were available. That’s why we decided to form United Therapeutics (UT) and dedicate ourselves to creating treatments for PAH.
Soon after we started that journey, our family spoke with others in similar situations and found there were limited support options available for people impacted by PAH. That’s when we realized UT could be doing more than creating new treatments.
We want to empower people throughout their PAH journeys—which is why support is such an integral part of our treatments. We are committed to helping people affected by PAH, until there is a cure.
Martine Rothblatt, PhD
Chairperson and CEO
United Therapeutics Corporation
How Can TYVASO Help Me?
TYVASO may help you do more in your day and do what matters most.
You May Have Side Effects
Talk to your healthcare provider and click below to learn more about potential side effects.